{"name":"Jemincare","slug":"jemincare","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"JMKX003142 Injection","genericName":"JMKX003142 Injection","slug":"jmkx003142-injection","indication":"Other","status":"phase_2"},{"name":"JMKX003142 tablets","genericName":"JMKX003142 tablets","slug":"jmkx003142-tablets","indication":"Other","status":"phase_2"},{"name":"JYB1907","genericName":"JYB1907","slug":"jyb1907","indication":"Other","status":"phase_1"},{"name":"Placebo+JYB1904","genericName":"Placebo+JYB1904","slug":"placebo-jyb1904","indication":"Other","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"JMKX001899","genericName":"JMKX001899","slug":"jmkx001899","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"JYB1904","genericName":"JYB1904","slug":"jyb1904","indication":"Relapsing multiple sclerosis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Sonidegib Phosphate Capsules","genericName":"Sonidegib Phosphate Capsules","slug":"sonidegib-phosphate-capsules","indication":"Locally advanced basal cell carcinoma (laBCC)","status":"marketed"}]}],"pipeline":[{"name":"JMKX001899","genericName":"JMKX001899","slug":"jmkx001899","phase":"phase_3","mechanism":"JMKX001899 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"JMKX003142 Injection","genericName":"JMKX003142 Injection","slug":"jmkx003142-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JMKX003142 tablets","genericName":"JMKX003142 tablets","slug":"jmkx003142-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JYB1904","genericName":"JYB1904","slug":"jyb1904","phase":"phase_3","mechanism":"JYB1904 is a small molecule targeting the S1P1 receptor.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"JYB1907","genericName":"JYB1907","slug":"jyb1907","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo+JYB1904","genericName":"Placebo+JYB1904","slug":"placebo-jyb1904","phase":"phase_3","mechanism":"JYB1904 is an investigational therapeutic being evaluated in combination with placebo control in a Phase 3 trial, though its specific molecular mechanism is not publicly disclosed.","indications":[],"catalyst":""},{"name":"Sonidegib Phosphate Capsules","genericName":"Sonidegib Phosphate Capsules","slug":"sonidegib-phosphate-capsules","phase":"marketed","mechanism":"Sonidegib is a Hedgehog pathway inhibitor that blocks Smoothened (SMO) signaling to suppress aberrant cell proliferation driven by Hedgehog pathway activation.","indications":["Locally advanced basal cell carcinoma (laBCC)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQYmZEVnVBTmdDM0s1SmtwS09STVo5NWY5S19iN0JTczNCZExScDM0MmRkcFRQRVViMlBiTk5sWGFYb1JBRDcxZnl4U0xZZWVKbFhhQmQwUWNBX3FvLUx0aksyMGxpMlBicU95ZGJINFJUNF9tNUxmYlNrU3d5VFBqc25tV29zeVdi?oc=5","date":"2024-12-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Pharmaceutical Technology","headline":"RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNSjNKVERLc0FaNzdsaGswNDJOWVRyNjN4dUs2WG1zOTBzQmpaMFB4R3hNRXdCLTNnWWtKeVFqWVhHeU84WlhpZ1hoemQtZTc3eHVnOUZUM0JPR055c1FTeXZnT1d2R1Vud3VkZ192T0VGNGNveUdjWmJYRlJndWMxRmNNY1c5cUdBSUlrMXgxLXFHNEd5QjdnQUJXY0p0dw?oc=5","date":"2024-12-23","type":"deal","source":"Yahoo Finance","summary":"RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - Yahoo Finance","headline":"RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPQ2VkNGd1cWk5MEVoRldvNnVXbGhJZVV3cVlIaGtZUi02bFNnNzM3VFVOWWFveFdhc2tEOF9NRl84eHc4bXpQeXJURmdZNXlwWjJDZEZNVFg0M1N2ZFhFSVozbk5Eb3ZrTEVmaF9vRm1TSENCNXZwcGF3VldjbU9sS1RnYVlvaXhEblRKZ20xcXd0UVlvc1FMbGt1MzZfVWU0T1Nld2R5R1lsQmN0N05LSFRTUUhrUDJOVVZFamtzV3NROVVFNFU0YTQxTQ?oc=5","date":"2023-12-26","type":"regulatory","source":"PR Newswire","summary":"Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs - PR Newswire","headline":"Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMHAtZjVZbzhZX2o4S01TVk9SRUZUTFV2MnZHa3pvQXFCbzdWUnByb005MENTQXVETlprYU0xTEY5R1l2X3dBXzBuZTNXM0gtWlE1WldwMWNVNWluX0c0OUtwRnUtVjB2NkxFTTFpeWhIbTU3OGpUSHlSOXp1WXFndVQ0Y0tTWmhzbHFWVmJBYXprZFJWZFZEbnU5c0p5bFBfY1dIRGFycy02YnNmbUpJ?oc=5","date":"2022-08-23","type":"deal","source":"BioWorld News","summary":"Jemincare out-licenses prostate cancer drug to Genentech in $650M deal - BioWorld News","headline":"Jemincare out-licenses prostate cancer drug to Genentech in $650M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTXgxdW02U21vajZtN0ZPRGdIQ2V1REI1RTlTdmVHNHBySHY2SWZ6dW8yMHJjRFdIekpKRENPZ25ud1pCUEF0SWRJeTNCSjBfbWFCZ2JVU19qOGo3OHd5YzkyVV9sRVQ5WnRCZWRlU3NvdDFKRVFXQlJCb2EwRUZPdG81WUVXT1RHTmtsb0VDWXQ3bFJiMW1wdlF0SU5SMUFMV2RhcGVqODhFTkRLeEE?oc=5","date":"2022-08-19","type":"patent","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Daiichi's ADC patent win; Roche's bet on Jemincare's PROTAC; AbbVie's CD47 retreat - Fierce Pharma","headline":"Fierce Pharma Asia—Daiichi's ADC patent win; Roche's bet on Jemincare's PROTAC; AbbVie's CD47 retreat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPX0lpdDNqZld0cS1faVg0aXdRM0VpdU1YX0phWkYxWGlCS1pnMFFjSVBFQ0NqQmRfbjIwUG9nY0FMSzdFVFI5eFVXVjFkYV9USmdtYlNiRXNqNThsWEtzUUhCTjhja1IzYXd4THBNRDJmel8tLVFSZDI2SzlQVkE3Mi1WV01VdVR0V193blp2MVEzdmJ6dEk4Mi0yLURpaWg5N3MtM0ZWTW4tMEpwbWpIaDlPOFNmbjk2XzRn?oc=5","date":"2022-08-18","type":"pipeline","source":"Fierce Biotech","summary":"China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful - Fierce Biotech","headline":"China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQRTM2ZU9vTy01dlV2eGY3VXRUZndGa0c1VlF1ekVPUThQLTE5TTllcktLQjB2VXZXemZOelhHaUh2b0VOUTd0N3JrdG94ck5yU3l5b1d2UUk2TzNiVjV4WXhOU1RtaUlvSlFteXBHMXNnNVFSWEdkUkt5bW5sck12X1hnVzBiT1VSQUxQMmFEeXd5RlowbjN3cDZLUURJWHdkNXZ0MmhWckVaY1N1MElJQ2ZObnZpZDhNcEt6UjFuLUxpQmEwWGFYX013?oc=5","date":"2021-11-30","type":"deal","source":"PR Newswire","summary":"Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO - PR Newswire","headline":"Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNSE9WUVo4dDNXYjFvajhEX25ibmRwVWZrZUhPcmtnYmpycGhvXzZ6QU5kVW1Hbko2d1RNd2k4RTVCeC1oSzJwdkZGWGtlUkl2c094RGZiVXd3bVB3ZG9EM3VNUndpZTVtZUpmNmdydlpjdXFkOXRZN0xYU0tkb0FydUw0d0ZhbTN4WWZtdTNDUHB1elkwWFBjTFdnYjZxUGtIRnVidkhtVEN6X2RM0gGyAUFVX3lxTE5PbDVtSi1DTVFIV01Hei04VkdfczFmajFvQUhJc1dOU1pkTEZSOE5JdEhMOWdWNGxwakh6VVNTTXZUc3hKeHFEMldGVVl5aHBzRVp1eDYweXdNdGtjMk1xX2t6Y3NNdnVlYzJjbkpmWEVIb3JBcTgzd0xpRjNTY2NzUjlUeW5Bdmp3R1IxWjlPOVF5bEZCMXhCTVNFWlA4d29UV1RfbzdONi10NzBsV3BNYkE?oc=5","date":"2021-08-26","type":"deal","source":"expresspharma.in","summary":"Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin - expresspharma.in","headline":"Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":3,"phase_2":2,"phase_1":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}